Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins

Changyi Chen, John D. Hughes, Samer G. Mattar, Stephen R. Hanson, Alan B. Lumsden

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Recently we designed an expanded polytetrafluoroethylene (ePTFE)-based local infusion device that delivers therapeutic agents directly through the graft wall in the region adjacent to the upstream anastomosis, thereby achieving a high drug concentration downstream along the graft-blood interface. In this study we evaluated the effects of infusing heparin by this method on graft patency and neointimal hyperplasia in a canine model of femoral vein replacement. Five dogs underwent bilateral femoral vein replacement with the device. In each case one graft was infused with continuous heparin (48 U/kg/day) while the contralateral control graft received phosphate-buffered saline solution for 14 days. All heparin-treated grafts were patent and all control grafts were thrombosed at 14 days. There was no significant difference in systemic activated partial thromboplastin time among samples taken preoperatively, at 48 hours, and at 14 days of implantation (p > 0.5). There was no significant difference in neointimal hyperplasia between the upstream and downstream anastomoses in heparin- treated grafts. These data demonstrate that the transgraft infusion of heparin preserved venous ePTFE graft patency without measurable systemic anticoagulation. Thus this approach may represent an attractive strategy for maintaining patency of synthetic venous grafts.

Original languageEnglish (US)
Pages (from-to)147-155
Number of pages9
JournalAnnals of Vascular Surgery
Volume10
Issue number2
DOIs
StatePublished - Mar 1996
Externally publishedYes

Fingerprint

Femoral Vein
Polytetrafluoroethylene
Heparin
Canidae
Thrombosis
Transplants
Hyperplasia
Equipment and Supplies
Partial Thromboplastin Time
Sodium Chloride
Phosphates
Dogs

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine

Cite this

Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins. / Chen, Changyi; Hughes, John D.; Mattar, Samer G.; Hanson, Stephen R.; Lumsden, Alan B.

In: Annals of Vascular Surgery, Vol. 10, No. 2, 03.1996, p. 147-155.

Research output: Contribution to journalArticle

Chen, Changyi ; Hughes, John D. ; Mattar, Samer G. ; Hanson, Stephen R. ; Lumsden, Alan B. / Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins. In: Annals of Vascular Surgery. 1996 ; Vol. 10, No. 2. pp. 147-155.
@article{8ce13f2b6f9642dc87367c2a3fe56327,
title = "Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins",
abstract = "Recently we designed an expanded polytetrafluoroethylene (ePTFE)-based local infusion device that delivers therapeutic agents directly through the graft wall in the region adjacent to the upstream anastomosis, thereby achieving a high drug concentration downstream along the graft-blood interface. In this study we evaluated the effects of infusing heparin by this method on graft patency and neointimal hyperplasia in a canine model of femoral vein replacement. Five dogs underwent bilateral femoral vein replacement with the device. In each case one graft was infused with continuous heparin (48 U/kg/day) while the contralateral control graft received phosphate-buffered saline solution for 14 days. All heparin-treated grafts were patent and all control grafts were thrombosed at 14 days. There was no significant difference in systemic activated partial thromboplastin time among samples taken preoperatively, at 48 hours, and at 14 days of implantation (p > 0.5). There was no significant difference in neointimal hyperplasia between the upstream and downstream anastomoses in heparin- treated grafts. These data demonstrate that the transgraft infusion of heparin preserved venous ePTFE graft patency without measurable systemic anticoagulation. Thus this approach may represent an attractive strategy for maintaining patency of synthetic venous grafts.",
author = "Changyi Chen and Hughes, {John D.} and Mattar, {Samer G.} and Hanson, {Stephen R.} and Lumsden, {Alan B.}",
year = "1996",
month = "3",
doi = "10.1007/BF02000759",
language = "English (US)",
volume = "10",
pages = "147--155",
journal = "Annals of Vascular Surgery",
issn = "0890-5096",
publisher = "Elsevier Inc.",
number = "2",

}

TY - JOUR

T1 - Transgraft infusion of heparin to prevent early thrombosis of expanded PTFE grafts in canine femoral veins

AU - Chen, Changyi

AU - Hughes, John D.

AU - Mattar, Samer G.

AU - Hanson, Stephen R.

AU - Lumsden, Alan B.

PY - 1996/3

Y1 - 1996/3

N2 - Recently we designed an expanded polytetrafluoroethylene (ePTFE)-based local infusion device that delivers therapeutic agents directly through the graft wall in the region adjacent to the upstream anastomosis, thereby achieving a high drug concentration downstream along the graft-blood interface. In this study we evaluated the effects of infusing heparin by this method on graft patency and neointimal hyperplasia in a canine model of femoral vein replacement. Five dogs underwent bilateral femoral vein replacement with the device. In each case one graft was infused with continuous heparin (48 U/kg/day) while the contralateral control graft received phosphate-buffered saline solution for 14 days. All heparin-treated grafts were patent and all control grafts were thrombosed at 14 days. There was no significant difference in systemic activated partial thromboplastin time among samples taken preoperatively, at 48 hours, and at 14 days of implantation (p > 0.5). There was no significant difference in neointimal hyperplasia between the upstream and downstream anastomoses in heparin- treated grafts. These data demonstrate that the transgraft infusion of heparin preserved venous ePTFE graft patency without measurable systemic anticoagulation. Thus this approach may represent an attractive strategy for maintaining patency of synthetic venous grafts.

AB - Recently we designed an expanded polytetrafluoroethylene (ePTFE)-based local infusion device that delivers therapeutic agents directly through the graft wall in the region adjacent to the upstream anastomosis, thereby achieving a high drug concentration downstream along the graft-blood interface. In this study we evaluated the effects of infusing heparin by this method on graft patency and neointimal hyperplasia in a canine model of femoral vein replacement. Five dogs underwent bilateral femoral vein replacement with the device. In each case one graft was infused with continuous heparin (48 U/kg/day) while the contralateral control graft received phosphate-buffered saline solution for 14 days. All heparin-treated grafts were patent and all control grafts were thrombosed at 14 days. There was no significant difference in systemic activated partial thromboplastin time among samples taken preoperatively, at 48 hours, and at 14 days of implantation (p > 0.5). There was no significant difference in neointimal hyperplasia between the upstream and downstream anastomoses in heparin- treated grafts. These data demonstrate that the transgraft infusion of heparin preserved venous ePTFE graft patency without measurable systemic anticoagulation. Thus this approach may represent an attractive strategy for maintaining patency of synthetic venous grafts.

UR - http://www.scopus.com/inward/record.url?scp=0029947499&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0029947499&partnerID=8YFLogxK

U2 - 10.1007/BF02000759

DO - 10.1007/BF02000759

M3 - Article

VL - 10

SP - 147

EP - 155

JO - Annals of Vascular Surgery

JF - Annals of Vascular Surgery

SN - 0890-5096

IS - 2

ER -